DK2608782T3 - Ny anvendelse af leflunomid og malononitrilamider - Google Patents
Ny anvendelse af leflunomid og malononitrilamider Download PDFInfo
- Publication number
- DK2608782T3 DK2608782T3 DK11754832.1T DK11754832T DK2608782T3 DK 2608782 T3 DK2608782 T3 DK 2608782T3 DK 11754832 T DK11754832 T DK 11754832T DK 2608782 T3 DK2608782 T3 DK 2608782T3
- Authority
- DK
- Denmark
- Prior art keywords
- spinal cord
- injury
- compound
- trauma
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (8)
1. Forbindelse med formlen (II)
eller et farmaceutisk acceptabelt salt, solvat, stereoisomer eller et derivat deraf til anvendelse ved behandling af en centralnervesystem-traume-relateret lidelse, hvor derivatet er en forbindelse med formlen III:
eller et farmaceutisk acceptabelt salt, solvat eller stereoisomer deraf.
2. Forbindelsen til anvendelse ifølge krav 1, hvori stereoisomeren af forbindelsen er R- eller S-enantiomeren.
3. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1 til 2, hvori den centralnervesystem-traume-relaterede lidelse er fuldstændig rygmarvsskade, delvis rygmarvsskade, rygmarv-kontusion, rygmarvskompression, rygmarvs-traume, rygmarvsskade, paraplegi, quadriplegi, tetraplegi, central-streng-syndrom, Brown-Séquard-syndrom, anterior-streng-syndrom, konus-medullaris-syndrom, cauda-equina-syndrom, traumatisk hjerneskade, TBI, hjernelæsion, hjerneskade, kranietraume, diffus axonal skade (DAI), hovedtraume, hjernerystelse, hjerne-kontusion, subduralt hæmatom, epidural hæmatom, subaraknoidal blødning, intracerebral blødning eller CNS-komprimering.
4. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1 til 2, hvori den centralnervesystem-traume-relaterede lidelse er en rygmarvsskade eller en rygmarvs-kontusion.
5. Farmaceutisk præparat til anvendelse ved forebyggelse og/eller behandling af CNS-traume-relateret lidelser, hvilket præparat omfatter en terapeutisk effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 4 i blanding med en farmaceutisk acceptabel bærer eller hjælpestof.
6. Det farmaceutiske præparat til anvendelse ifølge krav 5, hvori den centralnervesystem-traume-relaterede lidelse er fuldstændig rygmarvsskade, delvis rygmarvsskade, rygmarv-kontusion, rygmarvskompression, rygmarvs-traume, rygmarvsskade, paraplegi, quadriplegi, tetraplegi, central-streng-syndrom, Brown-Séquard-syndrom, anterior-streng-syndrom, konus-medullaris-syndrom, cauda-equina-syndrom, traumatisk hjerneskade, TBI, hjernelæsion, hjerneskade, kranietraume, diffus axonal skade (DAI), hovedtraume, hjernerystelse, hjerne-kontusion, subduralt hæmatom, epidural hæmatom, subaraknoidal blødning, intracerebral blødning eller CNS-komprimering.
7. Det farmaceutiske præparat til anvendelse ifølge krav 5, hvori den centralnervesystem-traume-relaterede lidelse er en rygmarvsskade eller en rygmarvs-kontusion.
8. Farmaceutisk præparat til anvendelse ved forebyggelse og/eller behandling af en rygmarvsskade eller en rygmarvs-kontusion, hvilket præparat omfatter en terapeutisk effektiv mængde af leflunomid i blanding med en farmaceutisk acceptabel bærer eller hjælpestof, hvori præparatet ikke indeholder en immun-modulerende forbindelse som en anden aktiv ingrediens.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37645310P | 2010-08-24 | 2010-08-24 | |
| EP10008802 | 2010-08-24 | ||
| PCT/EP2011/004218 WO2012025217A1 (en) | 2010-08-24 | 2011-08-23 | Novel use of leflunomide and malononitrilamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2608782T3 true DK2608782T3 (da) | 2016-09-05 |
Family
ID=44587762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11754832.1T DK2608782T3 (da) | 2010-08-24 | 2011-08-23 | Ny anvendelse af leflunomid og malononitrilamider |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8957098B2 (da) |
| EP (1) | EP2608782B1 (da) |
| JP (1) | JP5820476B2 (da) |
| CN (1) | CN103153295A (da) |
| DK (1) | DK2608782T3 (da) |
| ES (1) | ES2591355T3 (da) |
| WO (1) | WO2012025217A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE034890T2 (hu) | 2010-10-29 | 2018-03-28 | Algiax Pharmaceuticals Gmbh | Malononitrilaminok alkalmazása neuropathiás fájdalomban |
| EP3928772A1 (en) * | 2020-06-26 | 2021-12-29 | Algiax Pharmaceuticals GmbH | Nanoparticulate composition |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ES2124800T3 (es) | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion de interleuquina 1 beta. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6011051A (en) | 1996-07-31 | 2000-01-04 | Hoechst Aktiengesellschaft | Use of isoxazole and crotonamide derivatives for the modulation of apoptosis |
| US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| SI2282778T1 (sl) * | 2008-04-29 | 2017-07-31 | Pharnext | Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezo |
| EP2314291A1 (en) | 2009-10-22 | 2011-04-27 | Sanofi-Aventis | Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
-
2011
- 2011-08-23 CN CN201180040827XA patent/CN103153295A/zh active Pending
- 2011-08-23 DK DK11754832.1T patent/DK2608782T3/da active
- 2011-08-23 ES ES11754832.1T patent/ES2591355T3/es active Active
- 2011-08-23 JP JP2013525178A patent/JP5820476B2/ja active Active
- 2011-08-23 US US13/817,800 patent/US8957098B2/en active Active
- 2011-08-23 WO PCT/EP2011/004218 patent/WO2012025217A1/en active Application Filing
- 2011-08-23 EP EP11754832.1A patent/EP2608782B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130274301A1 (en) | 2013-10-17 |
| CN103153295A (zh) | 2013-06-12 |
| EP2608782A1 (en) | 2013-07-03 |
| JP2013536209A (ja) | 2013-09-19 |
| WO2012025217A1 (en) | 2012-03-01 |
| EP2608782B1 (en) | 2016-06-29 |
| ES2591355T3 (es) | 2016-11-28 |
| JP5820476B2 (ja) | 2015-11-24 |
| US8957098B2 (en) | 2015-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9468615B2 (en) | Use of malononitrilamides in neuropathic pain | |
| US20060122228A1 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| JP2007531770A (ja) | 睡眠不全、及び疾患に伴う睡眠不全の治療、予防、又は管理の方法、及びそれに用いる組成物 | |
| DK2608782T3 (da) | Ny anvendelse af leflunomid og malononitrilamider | |
| EP2685983B1 (en) | Novel use of imidazotriazinones | |
| US10472324B2 (en) | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | |
| KR101255578B1 (ko) | 뇌경색에 연관된 뇌혈관 장애를 치료하는데 유용한피라졸론 화합물 | |
| US20140057978A1 (en) | Novel use of benzofuranylsulfonates | |
| WO2013156231A1 (en) | Use of imidazotriazinones in neuropathic pain | |
| ES2726640T3 (es) | Derivados de 2-ciano-3-ciclopropil-3-hidroxi-n-aril-tioacrilamida | |
| US20170119775A1 (en) | Treatment of cognitive disorders |